Petra Nilsson
Overview
Explore the profile of Petra Nilsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piehl F, Alping P, Virtanen S, Englund S, Burman J, Fink K, et al.
Ann Neurol
. 2024 Jun;
96(4):678-693.
PMID: 38923558
Objective: To assess comparative effectiveness, safety, and tolerability of off-label rituximab, compared with frequently used therapies approved for multiple sclerosis (MS). Methods: A Swedish cohort study of persons with relapsing-remitting...
2.
Longinetti E, Englund S, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al.
J Neurol Neurosurg Psychiatry
. 2023 Aug;
95(2):134-141.
PMID: 37558400
Background: We analysed the COMparison Between All immunoTherapies for Multiple Sclerosis (NCT03193866), a Swedish nationwide observational study in relapsing-remitting multiple sclerosis (RRMS), to identify trajectories of processing speed and physical...
3.
Englund S, Kierkegaard M, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al.
Mult Scler Relat Disord
. 2023 Jan;
70:104481.
PMID: 36603296
Background: Fatigue is a debilitating symptom of multiple sclerosis (MS), but its relation to sociodemographic and disease-related characteristics has not been investigated in larger studies. The objectives of this study...
4.
Zervides K, Janelidze S, Nystedt J, Gullstrand B, Nilsson P, Sundgren P, et al.
BMC Neurol
. 2022 Dec;
22(1):467.
PMID: 36494778
Background: Neuronal damage in systemic lupus erythematosus (SLE) is common, but the extent and mechanisms are unclear. Neurofilament light (NfL) concentrations rise in plasma and cerebrospinal fluid (CSF) during neuronal...
5.
Longinetti E, Bower H, McKay K, Englund S, Burman J, Fink K, et al.
Ann Clin Transl Neurol
. 2022 Aug;
9(9):1449-1458.
PMID: 35993445
Objective: To estimate risks for all-cause mortality and for severe COVID-19 in multiple sclerosis patients and across relapsing-remitting multiple sclerosis patients exposed to disease-modifying therapies. Methods: We conducted a Swedish...
6.
Martensson J, Rumetshofer T, Nystedt J, Latt J, Nilsson P, Bengtsson A, et al.
Brain Sci
. 2021 Apr;
11(4).
PMID: 33923703
The purpose of this study is to investigate possible differences in brain structure, as measured by T1-weighted MRI, between patients with systemic lupus erythematosus (SLE) and healthy controls (HC), and...
7.
Wolf E, Grinneby D, Nilsson P, Priebe G
Eur J Oral Sci
. 2021 Mar;
129(3):e12782.
PMID: 33760322
The aim was to explore the experiences of sexually abused individuals as dental patients. Purposively selected were 13 informants (11 women) aged 19-56. All had experienced sexual abuse as children...
8.
Ryberg B, Arvidsson A, Bergkvist M, Nilsson P
J Neuroimmunol
. 2020 Apr;
343:577231.
PMID: 32302793
Autoimmune limbic encephalitis is part of CASPR 2 antibody-associated disease. A man with this rare disorder and a very high antibody titre had a unique history of laboratory exposure to...
9.
Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al.
Ann Neurol
. 2020 Feb;
87(5):688-699.
PMID: 32056253
Objective: Novel, highly effective disease-modifying therapies have revolutionized multiple sclerosis (MS) care. However, evidence from large comparative studies on important safety outcomes, such as cancer, is still lacking. Methods: In...
10.
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al.
JAMA Neurol
. 2019 Oct;
77(2):184-191.
PMID: 31589278
Importance: Although highly effective disease-modifying therapies for multiple sclerosis (MS) have been associated with an increased risk of infections vs injectable therapies interferon beta and glatiramer acetate (GA), the magnitude...